In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.

250,000

125,000

Upfront payments

$ 1,000,000

Reduction in rsearch and development expenses

30,000

Research and development expenses

208,000

130,000

Research and development expenses

4,000

56,000

Research and development expenses

272,000

46,000

Research and development expenses

63,000

141,000

Research and development expenses

639,000

827,000

Research and development expenses

81,000

82,000

Research and development expenses

133,000

Actuate stock of restricted shares

25,000

Fair value

$ 85,000

$ 111,000

Number of shares hold

13,889

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
	Jul. 23, 2021	Aug. 31, 2024	May 31, 2021	Jan. 31, 2018	Dec. 31, 2025	Dec. 31, 2024
Research and development expenses					$ 11,514,123	$ 16,125,690
Assignment Agreement [Member]
Upfront payments					25,000
BioNumerik Pharmaceuticals [Member] \| Assignment Agreement [Member]
Upfront payments				$ 25,000
Commitments description				In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.
AF Chemicals [Member] \| AFC License Agreement [Member]
Research and development expenses					250,000	125,000
Allarity Therapeuties [Member] \| Asset Purchase Agreement [Member]
Upfront payments	$ 1,000,000
Future payments	$ 1,000,000
Fortrea Inc [Member] \| Fortrea Agreement [Member]
Research and development expenses					2,028,000	5,487,000
Patheon API Services [Member] \| Patheon Agreement [Member]
Research and development expenses					20,000	18,000
Reduction in rsearch and development expenses						30,000
Piramal Pharma Solutions [Member] \| Piramal Pharma Agreement [Member]
Research and development expenses					208,000	130,000
Vivo Pharm [Member] \| Vivo Pharm Agreement [Member]
Research and development expenses					4,000	56,000
Fox Chase Cancer Center [Member] \| Research Agreement [Member]
Research and development expenses					272,000	46,000
Berkshire Sterile Manufacturing [Member] \| Berkshire Agreement [Member]
Research and development expenses					63,000	141,000
Shilpa Medicare Limited [Member] \| Shilpa Agreement [Member]
Research and development expenses					639,000	827,000
Curia Global, Inc. [Member] \| Curia Agreement [Member]
Research and development expenses					81,000	82,000
Harvest Integrated Research Organization [Member] \| Harvest Integrated Research Organization Agreement [Member]
Research and development expenses					133,000
Actuate Therapeutics [Member] \| Collaboration Agreement [Member]
Actuate stock of restricted shares			25,000
Nominal value acquired cost			$ 0
Fair value					$ 85,000	$ 111,000
Actuate Therapeutics [Member] \| Collaboration Agreement [Member] \| Reverse Stock Split and IPO [Member]
Number of shares hold		13,889